← Eichor
Study identifier: NCT07555574 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Defining Retinal Structures Using Hyperspectral Retinal Imaging

Condition: Age-Related Macular Degeneration · Diabetic Retinopathy · Glaucoma  ·  Sponsor: Center for Eye Research Australia

PhaseNA
Planned participants1000
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

This study evaluates hyperspectral retinal imaging as a novel, non-invasive imaging technique to characterise retinal and optic nerve structures in healthy individuals and patients with eye disease. Hyperspectral imaging captures retinal data across multiple wavelengths to generate detailed spectral information that may reveal features not visible with conventional retinal photography. Approximately 1000 participants will undergo multi-modal ophthalmic imaging in Melbourne, Australia, including hyperspectral imaging, OCT, fundus photography, and related tests. The study aims to compare hyperspectral imaging with standard imaging methods and assess its ability to identify retinal biomarkers associated with diseases such as diabetic retinopathy, glaucoma, and age-related macular degeneration.

This description comes directly from the study's public registry record.

Talk to the study team

Darvy Dang  ·  +61 3 9959 0102  ·  darvy.dang@unimelb.edu.au

Always discuss trial participation with your own doctor first.

Locations (1)

The Centre for Eye Research AustraliaMelbourne, Victoria, AustraliaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07555574